Study highlights causal associations between gut microbes and hypothyroidism

No­var­tis inked a deal to buy Mor­phoSys for $2.9 bil­lion, in a move that gives the Swiss Big Phar­ma a can­cer drug on the verge

Arti­va Bio­ther­a­peu­tics, a clin­i­cal-stage NK cell ther­a­py biotech, is try­ing again for the pub­lic mar­kets, it re­vealed Fri­day af­ter­noon in an SEC Sign up to